BA
ALXN

Boston Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Boston Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-33,142
Closed -$4.34M – 647
2019
Q2 		$4.34M Sell
33,142
-14,591
-31% -$1.88M 0.23% 119
2019
Q1 		$6.45M Buy
47,733
+209
+0.4% +$26K 0.33% 82
2018
Q4 		$4.63M Sell
47,524
-2,236
-4% -$264K 0.27% 104
2018
Q3 		$6.92M Sell
49,760
-201,089
-80% -$25.2M 0.3% 89
2018
Q2 		$31.1M Buy
250,849
+81,478
+48% +$9.52M 0.78% 22
2018
Q1 		$18.9M Buy
169,371
+20,130
+13% +$2.41M 0.48% 55
2017
Q4 		$17.8M Buy
149,241
+4,315
+3% +$525K 0.39% 70
2017
Q3 		$20.3M Sell
144,926
-9,815
-6% -$1.33M 0.46% 60
2017
Q2 		$18.8M Buy
154,741
+345
+0.2% +$40.2K 0.43% 61
2017
Q1 		$18.7M Buy
154,396
+34,315
+29% +$4.42M 0.44% 57
2016
Q4 		$14.7M Buy
+120,081
New +$14.7M 0.35% 84

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boston Advisors's ALXN Position: Q3 2019 in Review

Boston Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 33,142 shares — an estimated $4.34M sold.

Boston Advisors first reported a position in ALXN in Q4 2016 and held it in 11 quarters. The position peaked at $31.1M in Q2 2018. 646 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Boston Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Boston Advisors sold 33,142 Alexion Pharmaceuticals shares in Q3 2019, an estimated $4.34M.
  • Boston Advisors first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 11 quarters.
  • Boston Advisors's Alexion Pharmaceuticals position peaked at $31.1M in Q2 2018.
  • 646 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.